Khiron Adds One more Medical Cannabis Clinic Zerenia™ in Peru in partnership with Clínica del Dolor Lima
Khiron Life Sciences Corp., (TSXV: KHRN), (OTCQX: KHRNF), (Frankfurt: A2JMZC), a vertically-integrated, global operator in the field of medical cannabis, with its main operations in Europe and Latin America, has announced the launching of yet another Zerenia™ clinic in the country of Peru in Latin America, together with CDL, the specialized pain clinic which offers cannabis treatment to patients in pain who require it.
About Khiron Life Sciences Corp.
Khiron is one of the frontrunners in the field of medical cannabis at a global level, though its main operations are restricted to Europe and Latin America. The company’s approach is patient-oriented, and it combines this with its scientific expertise, innovation techniques, and physician education agendas, thereby fully leveraging its wholly-owned health clinics and telemedicine platforms.
The company focuses fully on facilitating access to brand loyalty and on driving prescriptions. Khiron is active in the markets of Peru, Colombia, Brazil, Germany, and the UK, and is poised to soon enter the market in Mexico.
Benefits of Launching in Peru
- The setting up of the new clinic increases the number of clinics operated by the company to 16, at the global level. These clinics are in the UK, Peru, and Colombia.
- The sales in Peru in 2021 had amounted to 5% of Khiron’s total Latin America sales in that year.
- The earliest Zerenia clinic was opened by the company in Lima, in the latter half of the year 2021, in strategic partnership with the Lima-based medical company Clinica Montesur. After the clinic was opened, more than 80% of patient consultations have led to prescriptions of cannabis.
- Khiron got the approval of Peruvian authorities for its two initial medicinal cannabis products and had them registered by August 2021. They became available across the country for purchase towards the end of the fourth quarter of the year 2021.
Partnering with CDL
Clínica del Dolor Lima (CDL) is already a well-established pain management clinic and its patient population consists exclusively of those having acute or chronic pain. Having joined hands with this pain clinic which has many medical specialists working for them, Khiron will be fully making use of the existing infrastructure of CDL, and providing access to treatments using THC and CBD (cannabinoids), to an increasing number of patients in the capital city of Lima and its suburbs.
Alvaro Torres, Director, and CEO of Khiron said that in 2021, of the company’s total Latin American sales, 5% was that of Peru. He expressed hope that with the new venture with CDL, the company could increase its sales quite cost-effectively by increasing the number of Zerenia clinics in Peru.
Even with the first clinic the company had started in Peru, more than 80% of consultations had led to prescriptions of medical cannabis and this was sufficient proof that the company’s service-driven policy was quite successful.
As such, according to him, with the establishment of pain-focused collaboration in Lima with CDL, Khiron was planning to increase their capacity further so that they would be able to offer a range of treatment options for the over 10,000 patients they had.
Khiron had already started making the company’s registered medical products available through the many drugstores in Peru, thereby making it easier for cannabis patients to access them. This in turn was bound to fuel the company’s growth.
Torres emphasized how excited he was about the new partnership that would allow his company to explore diverse business models for expanding the Zerenia clinics and achieving increased growth in Peru with its population of more than 32 million.